Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHRP-2 is used in research to induce robust GH pulses and study anabolic and metabolic effects; clinically developed as pralmorelin for GH deficiency diagnostics6272, Sermorelin is used as a diagnostic agent for assessing GH secretory capacity and as a research tool or off-label therapy to increase endogenous GH in GH-deficient or age-related contexts1727.
While GHRP-2 works as a second-generation hexapeptide growth hormone–releasing peptide that mimics ghrelin by agonizing GHSR-1a, strongly stimulating pulsatile GH release and modestly raising prolactin, ACTH, and cortisol62723096, Sermorelin is a synthetic 29-amino-acid peptide identical to the 1–29 N-terminal fragment of human GHRH that stimulates GH synthesis and secretion by binding pituitary GHRH receptors1727120.
GHRP-2
GHSR
Sermorelin
GHRH
Both peptides fall into a similar broad context as Hormone peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while GHRP-2 is more of a hormone peptide and Sermorelin is better described as a hormone peptide. Both appear to work through Receptor agonist, which is one of the main reasons they can look related despite other differences. GHRP-2 has a more synthetic design origin, while Sermorelin is closer to synthetic analog background and their development context also differs, with GHRP-2 in Clinical phase 1 while Sermorelin is approved. Their sequence patterns also diverge, with GHRP-2 showing protein-mimetic sequence features and Sermorelin showing alpha-helical domain features.
No related articles are linked to these peptides yet.